The timeliness of COVID-19 testing and tracing in eight public health regions in the Netherlands

Autor: JR Bosdriesz, EM den Boogert, NHTM Dukers-Muijrers, HM Götz, IE Goverse, T Leenstra, SFH Raven, SKS van Dijken, K Wevers, AA Matser

Publikováno v: European Journal of Public Health. 32

Background Testing and Contact Tracing (TCT) was a core strategy in the fight against the spread of SARS-CoV-2. However, little is known about the real-world effectiveness of TCT for COVID-19. Because time is an important conditional factor, we aim t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b6e96c7d62b5e2f1d16999a4ea7b446
https://doi.org/10.1093/eurpub/ckac130.020

Self-reported symptoms as predictors of SARS-CoV-2 infection in the general population living in the Amsterdam region, the Netherlands.

Autor: Bosdriesz JR; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Ritsema F; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Leenstra T; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., Petrignani MWF; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., Bruisten SM; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Medical Microbiology, Amsterdam Infection & Immunity Institute (AII), Amsterdam University Medical Center (UMC), Amsterdam, The Netherlands., Coyer L; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Schreijer AJM; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., van Duijnhoven YTHP; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., Schim van der Loeff MF; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Matser AA; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Publikováno v: PloS one [PLoS One] 2022 Jan 28; Vol. 17 (1), pp. e0262287. Date of Electronic Publication: 2022 Jan 28 (Print Publication: 2022).

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.

Autor: Fraser H; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: hannah.fraser@bristol.ac.uk., Martin NK; Division of Global Public Health, University of California, San Diego, San Diego, CA, USA; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Brummer-Korvenkontio H; National Institute for Health and Welfare, Helsinki, Finland., Carrieri P; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France., Dalgard O; University of Oslo, Oslo, Norway; Akershus University Hospital, Lørenskog, Norway., Dillon J; University of Dundee, Dundee, Scotland, UK., Goldberg D; Health Protection Scotland, Glasgow, Scotland, UK., Hutchinson S; Glasgow Caledonian University, Glasgow, Scotland, UK; Health Protection Scotland, Glasgow, Scotland, UK., Jauffret-Roustide M; French Institute for Public Health Surveillance, St. Maurice, France; CERMES3 (Inserm U988/UMR CNRS 8211/EHESS/Paris Descartes University), Paris, France., Kåberg M; Department of Medicine, Huddinge, Division of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Matser AA; Public Health Service of Amsterdam, Amsterdam, The Netherlands; University Medical Center Utrecht, Utrecht, The Netherlands., Matičič M; University of Ljubljana, Ljubljana, Slovenia; University Medical Centre Ljubljana, Ljubljana, Slovenia., Midgard H; University of Oslo, Oslo, Norway., Mravcik V; National Monitoring Centre for Drugs and Drug Addiction, Prague, Czech Republic; Charles University and General University Hospital in Prague, Prague, Czech Republic; National Institute of Mental Health, Klecany, Czech Republic., Øvrehus A; Odense University Hospital, Odense, Denmark., Prins M; Public Health Service of Amsterdam, Amsterdam, The Netherlands; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands., Reimer J; HealthNorth, Bremen, Germany; University of Hamburg, Hamburg, Germany., Robaeys G; Ziekenhuis Oost-Limburg, Genk, Belgium; Hasselt University, Diepenbeek, Belgium; University Hospital Leuven, Leuven, Belgium., Schulte B; University of Hamburg, Hamburg, Germany., van Santen DK; Public Health Service of Amsterdam, Amsterdam, The Netherlands., Zimmermann R; Robert Koch Institute, Berlin, Germany., Vickerman P; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Hickman M; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Publikováno v: Journal of hepatology [J Hepatol] 2018 Mar; Vol. 68 (3), pp. 402-411. Date of Electronic Publication: 2018 Jan 08.